Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 5, Pages 1125
Publisher
MDPI AG
Online
2020-05-05
DOI
10.3390/cancers12051125
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comprehensive T cell repertoire characterization of non-small cell lung cancer
- (2020) Alexandre Reuben et al. Nature Communications
- Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
- (2020) Xiao-Xiao Peng et al. Journal for ImmunoTherapy of Cancer
- Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
- (2020) Hiro Sato et al. International Journal of Clinical Oncology
- Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of KEYNOTE-010 trial
- (2019) R S Herbst et al. ANNALS OF ONCOLOGY
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11
- (2019) Linnéa La Fleur et al. LUNG CANCER
- Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays
- (2019) Ping Qiu et al. Scientific Reports
- Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
- (2019) Zhijie Wang et al. JAMA Oncology
- Phenotype of POLE-mutated endometrial cancer
- (2019) Sara Imboden et al. PLoS One
- Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer
- (2019) Yen-Lin Chen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
- (2019) Natasha B. Leighl et al. CLINICAL CANCER RESEARCH
- Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors.
- (2019) Jasgit C. Sachdev et al. JOURNAL OF CLINICAL ONCOLOGY
- K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
- (2019) Matthias Scheffler et al. Journal of Thoracic Oncology
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer
- (2019) Hao Chen et al. CANCER SCIENCE
- The biological functions and clinical applications of exosomes in lung cancer
- (2019) Rui Chen et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma
- (2019) Akiko Arakawa et al. Frontiers in Immunology
- Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
- (2019) Menno Tamminga et al. Journal for ImmunoTherapy of Cancer
- Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
- (2019) Alama et al. Journal of Clinical Medicine
- Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
- (2019) Melanie Janning et al. Cancers
- Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
- (2019) Andrew Georgiadis et al. CLINICAL CANCER RESEARCH
- The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer
- (2019) Taher Abu Hejleh et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types
- (2019) Feng Wang et al. JAMA Oncology
- Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
- (2019) Carlo Genova et al. Journal of Clinical Medicine
- LBA79Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials
- (2019) R S Herbst et al. ANNALS OF ONCOLOGY
- LBA80Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
- (2019) L Paz-Ares et al. ANNALS OF ONCOLOGY
- B7-H4, a promising target for immunotherapy
- (2019) Jia-Yu Wang et al. CELLULAR IMMUNOLOGY
- Liquid biopsy tracking of lung tumor evolutions over time
- (2019) Alessandro Russo et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade
- (2019) Miriam Möller et al. JOURNAL OF IMMUNOTHERAPY
- MA25.04 Blood-Based Tumor Mutation Burden as a Predictive Biomarker for Outcomes After Pembrolizumab Based First Line Therapy in Metastatic NSCLC
- (2019) C. Aggarwal et al. Journal of Thoracic Oncology
- OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial
- (2019) N. Rizvi et al. Journal of Thoracic Oncology
- Serial ultra‐deep sequencing of circulating tumor DNA reveals the clonal evolution in non‐small cell lung cancer patients treated with anti‐PD1 immunotherapy
- (2019) Li Li et al. Cancer Medicine
- The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
- (2019) Andrew A. Davis et al. Journal for ImmunoTherapy of Cancer
- Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges
- (2019) Erika Rijavec et al. Cancers
- Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer
- (2018) H Wang et al. ANNALS OF ONCOLOGY
- PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
- (2018) Marzia Del Re et al. BRITISH JOURNAL OF CANCER
- HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer
- (2018) Tristan A Barnes et al. BRITISH JOURNAL OF CANCER
- The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients
- (2018) Minglei Zhuo et al. Cancer Biomarkers
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Exosome-Mediated Regulation of Tumor Immunology
- (2018) Naohiro Seo et al. CANCER SCIENCE
- Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
- (2018) Sarah B. Goldberg et al. CLINICAL CANCER RESEARCH
- Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
- (2018) Brandon W. Higgs et al. CLINICAL CANCER RESEARCH
- Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer
- (2018) Yusuke Okuma et al. Clinical Lung Cancer
- Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung Cancer
- (2018) Alona Zer et al. Clinical Lung Cancer
- Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments
- (2018) Shota Omori et al. International Journal of Clinical Oncology
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non–Small-Cell Lung Cancer
- (2018) Antoine Legras et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief Report
- (2018) Yuki Owada-Ozaki et al. Journal of Thoracic Oncology
- IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC)
- (2018) Christian Rolfo et al. Journal of Thoracic Oncology
- Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer
- (2018) Zhengbo Song et al. LUNG CANCER
- PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
- (2018) Nicolas Guibert et al. LUNG CANCER
- Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1
- (2018) Liang Liu et al. Molecular Cancer
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)
- (2018) Silvia Vecchiarelli et al. Oncotarget
- Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab
- (2018) Adrien Costantini et al. OncoImmunology
- Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer
- (2018) Etienne Giroux Leprieur et al. OncoImmunology
- Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
- (2018) Chunyan Yue et al. OncoImmunology
- Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma
- (2018) Chee Khoon Lee et al. JAMA Oncology
- Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
- (2018) Patrick Danaher et al. Journal for ImmunoTherapy of Cancer
- Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.
- (2018) Fatema A. Legrand et al. JOURNAL OF CLINICAL ONCOLOGY
- A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
- (2018) Roger Sun et al. LANCET ONCOLOGY
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interferon gamma in cancer immunotherapy
- (2018) Ling Ni et al. Cancer Medicine
- Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
- (2018) Hongshu Sui et al. Journal of Immunology Research
- LBA55Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
- (2018) E S Kim et al. ANNALS OF ONCOLOGY
- Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
- (2018) Francesco Passiglia et al. BRITISH JOURNAL OF CANCER
- Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer
- (2018) Valsamo Anagnostou et al. CANCER RESEARCH
- Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy
- (2018) Mark Ayers et al. CLINICAL CANCER RESEARCH
- Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer
- (2018) Robert Pirker CURRENT OPINION IN ONCOLOGY
- Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
- (2018) Arsela Prelaj et al. EUROPEAN JOURNAL OF CANCER
- The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC
- (2018) Giulia Mazzaschi et al. LUNG CANCER
- Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
- (2018) Sabrina A. Hogan et al. Cancer Immunology Research
- Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies
- (2018) Aixa E. Soyano et al. Journal for ImmunoTherapy of Cancer
- Very early response of circulating tumour–derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non–small cell lung cancer
- (2017) Yuki Iijima et al. EUROPEAN JOURNAL OF CANCER
- Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)
- (2017) Frédéric Bigot et al. EUROPEAN JOURNAL OF CANCER
- Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas
- (2017) Sehui Kim et al. EUROPEAN JOURNAL OF CANCER
- PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
- (2017) Pedro N Aguiar et al. Immunotherapy
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- (2017) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1
- (2017) Anthousa Kythreotou et al. JOURNAL OF CLINICAL PATHOLOGY
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
- (2017) Stefan Diem et al. LUNG CANCER
- Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
- (2017) Stephen J. Bagley et al. LUNG CANCER
- Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy
- (2017) Thomas J Gniadek et al. MODERN PATHOLOGY
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coding and noncoding landscape of extracellular RNA released by human glioma stem cells
- (2017) Zhiyun Wei et al. Nature Communications
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer
- (2017) Estela Maria Silva et al. PLoS One
- Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
- (2016) David Y. Oh et al. CANCER RESEARCH
- STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
- (2016) S. Koyama et al. CANCER RESEARCH
- Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
- (2016) Takaaki Tokito et al. EUROPEAN JOURNAL OF CANCER
- The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis
- (2016) Pedro N Aguiar et al. Immunotherapy
- Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
- (2016) Janice M. Mehnert et al. JOURNAL OF CLINICAL INVESTIGATION
- Exosomes and tumor-mediated immune suppression
- (2016) Theresa L. Whiteside JOURNAL OF CLINICAL INVESTIGATION
- CD8+T Cells Play a Bystander Role in Mice Latently Infected with Herpes Simplex Virus 1
- (2016) Kevin R. Mott et al. JOURNAL OF VIROLOGY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
- (2016) Sumit K. Subudhi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer
- (2016) Wen Feng et al. Oncotarget
- Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer
- (2015) T. Donnem et al. ANNALS OF ONCOLOGY
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer
- (2015) J. Chen et al. ANNALS OF ONCOLOGY
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
- (2015) M. Ilie et al. ANNALS OF ONCOLOGY
- Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis
- (2015) Yiting Geng et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer
- (2015) Kurt A. Schalper et al. JNCI-Journal of the National Cancer Institute
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
- (2015) M B Schabath et al. ONCOGENE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
- (2015) F. Skoulidis et al. Cancer Discovery
- Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer
- (2015) Kurt A. Schalper et al. JNCI-Journal of the National Cancer Institute
- CD45RO+ Memory T Lymphocytes — a Candidate Marker for TNM-Immunoscore in Squamous Non–Small Cell Lung Cancer
- (2015) Erna-Elise Paulsen et al. NEOPLASIA
- Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab
- (2015) Jon Bjoern et al. OncoImmunology
- Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
- (2015) Michael A. Postow et al. Journal for ImmunoTherapy of Cancer
- CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
- (2014) L. Robert et al. CLINICAL CANCER RESEARCH
- Liquid Biopsies: Genotyping Circulating Tumor DNA
- (2014) Luis A. Diaz et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
- (2014) E. Cha et al. Science Translational Medicine
- Human Pol ɛ-dependent replication errors and the influence of mismatch repair on their correction
- (2013) Anderson Ayuk Agbor et al. DNA REPAIR
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Liquid biopsy: monitoring cancer-genetics in the blood
- (2013) Emily Crowley et al. Nature Reviews Clinical Oncology
- Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
- (2013) Jong-Mu Sun et al. PLoS One
- Clinical significance of B7-H4 expression in matched non-small cell lung cancer brain metastases and primary tumors
- (2013) Zhen-ye Li et al. OncoTargets and Therapy
- KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy
- (2012) Ji-lin Guan et al. ANNALS OF SURGICAL ONCOLOGY
- Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas
- (2012) Claire Palles et al. NATURE GENETICS
- Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status
- (2012) She-Juan An et al. PLoS One
- Unique Ectopic Lymph Node-Like Structures Present in Human Primary Colorectal Carcinoma Are Identified by Immune Gene Array Profiling
- (2011) Domenico Coppola et al. AMERICAN JOURNAL OF PATHOLOGY
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- (2011) Rui-Ru Ji et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer
- (2011) R K Gill et al. ONCOGENE
- Subtle variations in Pten dose determine cancer susceptibility
- (2010) Andrea Alimonti et al. NATURE GENETICS
- Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung Neoplasms
- (2009) Enrico Ruffini et al. ANNALS OF THORACIC SURGERY
- Density of Tumor-Infiltrating Lymphocytes Correlates with Disease Recurrence and Survival in Patients with Large Non-Small-Cell Lung Cancer Tumors
- (2009) Arman Kilic et al. JOURNAL OF SURGICAL RESEARCH
- Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures
- (2008) Marie-Caroline Dieu-Nosjean et al. JOURNAL OF CLINICAL ONCOLOGY
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
- (2008) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started